Found 471 investors
Anne Wojcicki
San Francisco, California, United States
Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to ...
Individual/Angel
Seed
Pre-Seed
Past Investments
23andMe, Gabbi, Bristle, Marley Medical, SteadyMD, Gameto, HALO Diagnostics, Getlabs, Sidecar Health, Multiverse, TMRW Life Sciences, ixLayer, Tesorio, Apeel Sciences, Base, Seqster, Adyn, theator, Midi Health, Prenuvo, Halo, Deep Instinct, Volta Labs
Armen Shanafelt
Indianapolis, Indiana, United States
Armen Shanafelt brings over 22 years of experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures. Previo...
Investment Partner
Past Investments
Avid Radiopharmaceuticals, GlobeImmune, Sutro Biopharma, Cerulean Pharma, Numerate, Symic Biomedical, Intradigm Corporation, Protagonist Therapeutics, Conforma Therapeutics, Lysosomal Therapeutics, Kymera Therapeutics, Serenex, Aileron Therapeutics, Surface Oncology, Receptos, CGI Pharmaceuticals, Hydra Biosciences, Nimbus Therapeutics, InnoCentive, FORMA Therapeutics, Cylene Pharmaceuticals, Aeglea BioTherapeutics, Cabrellis Pharmaceuticals, Nanostream Inc., MedManage Systems, Cavion, NexCura, Viamet Pharmaceuticals, Coherus Biosciences, Remon Medical Technologies, Bayhill Therapeutics, Viracta Therapeutics, Fluidigm, Trinity Biosystems
Ashpi Gupta
United Kingdom
Fleming Family & Partners was a private equity firm based in London, United Kingdom. The firm preferred to invest in the beverages, energy production, biotechnology, gold mining, broadcasting, radio, television, insurance and re-insurance sectors. The firm got merged with the London, United Kingdom based rival Stonehage Fleming to become the largest independent multifamily office business in Europe, the Middle East and Africa.
Private Equity Firm
Past Investments
InMobi, Exclusivelyin, Vliv, Reverse Logistics, Dhama Innovations
Bart Dessaint
United States
Mr. Talli Somekh is a Co-Founder of Musea Ventures. He co-founded and served as Acting Director, Business Development in Designer Energy. He is a Co-Founder and Board Member of White Dog Labs. He served as Chairman and Chief Executive Officer at Appsoma. He co-founded and served as Board Member at CloudPassage. He is also an Angel Investor. Mr. Somekh also Co-Founded and served as Executive Chairman at CloudPassage. He began his career participating in open source software communities developing web frameworks, databases, programming languages and revision control systems. His early training working with developers in the trenches has been invaluable in his transition to venture capital. As a co-founder and General Partner of Musea Ventures, he has applied his experience to investments in the areas of next-generation biotechnology and information technology. He has led Musea's investments in Acoustic Cytometry Systems (acquired by Life Technologies), Avantome (acquired by Illumina), Designer Energy, MobileVerbs, SpaceCurve, Verdezyne and Virident. He holds a degree from Tufts University and Pomona College.
Individual/Angel
Past Investments
KelDoc
Chris Christoffersen
Boulder, Colorado, United States
Chris joined Morgenthaler Ventures in 2001. Based in Boulder, Colorado, he is focusing on new biotechnology investments. Previously, he w...
Investment Partner
Past Investments
Shoulder Innovations, Medisix Therapeutics, Gemini Therapeutics, Locanabio, Claret Medical, Relievant Medsystems, Carrick Therapeutics, Catabasis Pharmaceuticals, Flex Pharma, Disarm Therapeutics, Cyteir Therapeutics, Cerevance, Nimbus Therapeutics, Catamaran Bio, Willow, ALX Oncology, Nimbus Apollo, Tallac Therapeutics, Nuvaira, Atsena Therapeutics, Cala Health, Tizona Therapeutics, Bold Penguin, Earlens Corporation, Ra Pharmaceuticals, FIRE1
Dan Becker
New York, New York
Managing Director at Access Biotechnology
BioTech
Pharmaceuticals
Therapeutics
Seed
Pre-Seed
Past Investments
Square, Strava, Almanac Beer Company, Neurana Pharmaceuticals, Pandion Therapeutics, Day One Biopharmaceuticals, Curie Therapeutics
Dan Forootan
United States
Mr. Raymond McCauley served as Chairman of Digital Biology at Singularity University. Mr. McCauley serves as Advisor at FREDsense Technologies. He also is an Angel Investor. He serves as an Advisor at Basepaws. He is a scientist, engineer and entrepreneur working at the forefront of biotechnology. He explores how applying technology to life - biology, genetics, medicine, agriculture - is affecting every one of us. He is known for using storytelling and down-to-earth examples to show how quickly these changes are happening, right now. Co-founder and Chief Architect for BioCurious, the hackerspace for biotech, a not-for-profit where professional scientists, DIYbio hobbyists and entrepreneurs come together to design the next big thing to come out of a Silicon Valley garage. Part of the team that developed next-generation DNA sequencing at Illumina, where he worked in bioinformatics, cancer sequencing and personal genomics.
Individual/Angel
Seed
Pre-Seed
Past Investments
Grin.co
David Wesson
United States
De Novo Ventures is a venture capital firm that specializes in the early stage to late stage investments. The firm Prefers to invest in the medical devices and biotechnology sectors. It is based in Saratoga, California and was founded in 2000.
Venture Capital
Seed
Early Stage Venture
Past Investments
ELLANSA
Jonathan Wolfson
San Francisco, California, United States
Jonathan Wolfson is Chief Executive Officer and co-founder of Solazyme. Solazyme is a leading industrial biotechnology company producing re...
Individual/Angel
Seed
Past Investments
Zently
Ken Powell
London, England, United Kingdom
Prior to his current role, Ken had very extensive experience of the Biotechnology sector. In reverse order he was: Executive Chairman of Q-C...
Individual/Angel
Seed
Past Investments
Q Chip
Kiran Mazumdar-Shaw
Bangalore, Karnataka, India
Kiran Mazumdar-Shaw is Chairperson and Managing Director of Biocon Limited, a biotechnology company based in Bangalore, India. Kiran is h...
Investment Partner
Individual/Angel
Seed
Past Investments
ThePrint, BUGWORKS Research, UE LifeSciences
Mitch Lasky
United States
Dr. William Radany serves as Angel Investor at E. William Radany. He is an Angel Investor. Dr. William Radany served as President and Chief Executive Officer at Verdezyne. He was a Board Member of xF Technologies. Prior to joining Verdezyne, he was the President and CEO of High Throughput Genomics, a provider of novel array-based gene expression assay technology for the life science industry. Previously, Dr. Radany was President of Biacore and founder and CEO of NeoGenex. Dr. Radany has held executive positions at Xencor, Caliper Technologies and Stratagene, where he helped establish business relationships with pharmaceutical and biotechnology companies. Dr. Radany received his Bachelor of Science degree in Cell Biology from Colorado State University and a Ph.D. in Biochemistry/Physiology from the University of Wyoming.
Individual/Angel
Series B
Series A
Past Investments
Manticore Games, Discord, Cyanogen, Thatgamecompany, PlayFab, Engine Yard, Outpost, Meteor Entertainment, PlayFab, Inc., CYNGN, Snap Inc., NaturalMotion, Red Robot Labs, Gaikai, Vivox, HipLogic
Mohammad Chowdhury
United Kingdom
Dr. Fintan Walton is the Founder and serves as Chief Executive Officer & Board Member at PharmaVentures. Over a period of three decades, Fintan has built PharmaVentures into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have also included major banks, investment/merchant banks, as well as private equity and venture capital groups. Dr Walton majored in Genetics at Trinity College Dublin, Ireland, where he also gained a Ph.D. Prior to his entrepreneurial activities at PharmaVentures, Fintan had built his R&D and commercial experience in biotechnology within management positions at Bass and Celltech plc (1982-1992). In 1996, he also founded PharmaDeals, the leading database and publishing business related to deal making data and analytics. Thousands of customers from around the world either bought or subscribed to these PharmaDeals publications. The PharmaDeals business was sold to IMS Health (now IQVIA) in Aug 2012.
Individual/Angel
Past Investments
GPM Investments, LAZ Karp
Naheed Kurji
Toronto, Ontario, Canada
Naheed Kurji is the President and CEO of Cyclica, a Toronto-based biotechnology company that leverages artificial intelligence and computati...
Individual/Angel
Past Investments
Cyclica
Noel Hall
British Columbia, Canada, North America
Mr. Noel Hall is a consultant to the life sciences industry with over 25 years of experience in the biotechnology sector. He was the Co-foun...
Individual/Angel
Past Investments
Incisive Genetics
Sarah Hodges
United States
Dr. Kim Kamdar serves as a Partner at Domain Associates. She is a Co-Founder and serves as Chairman at Seraphina Therapeutics. She serves as Advisory Board Member at Adjuvant Capital. She serves as Board Member at Epitel. She serves as Managing Partner at Medical Excellence Capital. She also serves as Board Member at San Diego Venture Group, Neothetics, Singular Genomics, Epic Sciences, Chairperson of Nominating and Corporate Governance Committee, and Member of Compensation Committee at Obalon Therapeutics. She served as Board Member at Omniome and Aspen Neuroscience. She is a Co-Founder of Truvian Sciences and also serves as its Board Member. She joined Domain in 2005 and became a partner in 2011. Prior to joining MPM, she was a research director at Novartis. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. She serves as an advisory board member of Eric Topol's NIH-supported Clinical and Translational Science Award for Scripps Medicine and of Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies.
Individual/Angel
Seed
Past Investments
Hello Tickets, Dunwello, VentureApp, JobGet
Stuart Roden
United States
Mr. V. R. Kaundinya is an Angel Investor. He serves as Board Member at Axis Bank. He served as Board Member at Advanta Growth Capital. Ram Kaundinya is an expert in the field of agriculture and specifically with reference to the business of agricultural inputs. He has a total experience of about 36 years which includes 22 years in the agrochemical industry and 14 years in the seed and biotech industry. Mr Kaundinya was the Managing Director and CEO of Advanta Ltd, an Indian seed company with global foot print from 2006 to 2013. In this capacity he was responsible for running the global business spread across various continents. The area of operation extended from Australia in the East to Argentina in the West . He led the global leadership team consisting of senior managers from different countries. Travelled extensively across the world and got exposed to agriculture and agri input markets in different parts of the world. Prior to this Mr Kaundinya held many posts of responsibility which included Managing Director of Emergent Genetics India and Managing Director of Cyanamid Agro during which he led multifunctional teams consisting of research, manufacturing, finance, supply chain, HR and Sales & marketing in seeds and agrochemicals industries. Prior to this he also served as the Director of the Agricultural Products Division of Cyanamid India and also served Hoechst India for thirteen years as a senior member of the management team of their agrochemicals division. Starting with sales and marketing during the long career Mr Kaundinya handled General Management and P&L responsibility for the last 16 years. Mergers and Acquisitions was a major area of expertise that he developed especially in the last 14 years, having led his companies in multiple transactions across the world. Mr. Kaundinya has always been associated with various industry associations. He was the Chairman of the Crop Life India (the then Indian Crop Protection Association) for two years from1998-2000. He was the Director of the Association of Seed Industry (ASI), Mumbai from 2002 to 2006. He is currently the Director General of the Agricultural Group of the biotech industry association called ABLE. He has been at the forefront of the expansion of biotechnology applications in agriculture in India. He has a wide experience in the area of policy advocacy for agricultural input industry. Kaundinya holds a PGDM with specialization in Agriculture from Indian Institute of Management, Ahmedabad. He is a graduate in Agriculture from the Andhra Pradesh Agricultural University. Kaundinya has been involved with academics for the last 30 years. He is a frequent guest lecturer at various management institutes. He teaches courses in Marketing and Corporate Strategy. Mr Kaundinya is a writer. He has co-authored a book titled 'Agri Input Marketing in India' with Prof Venugopal of XLRI. The book is just released. He currently consults independently for companies and funds operating in the field of agriculture. Mr. Kaundinya serves as an independent director on the boards of Axis Bank, Axis Finance and Syngenta India and as a non-Executive Director on the board of Advanta Ltd.
Individual/Angel
Past Investments
Trigo, Anima App, Granulate, Mozper, retrain.ai, Codota, Jones, Acumen.io
Vijay Ullal
United States
Dr. Stephen Pollitt is an Angel Investor. He served as Board Member at Sand Hill Angels. He has over 19 years experience in the biotechnology and pharmaceutical industries. His career began with Scios (later acquired by Johnson & Johnson) where he was in charge of host cell development for biologics heading into clinical testing. One of these products, Natrecor, received FDA approval in 2001 as a treatment for acute congestive heart failure. He served as Project Leader on several early phase drug discovery and development projects, most recently as Compound Development Team Lead for VEGF-121. He also served on the target selection committee which evaluated targets for the company's small molecule development platform. Steve is currently an independent consultant working with drug development teams at start-ups and virtual companies where he assists with management of the drug development process and molecular biology of protein expression. Steve holds a Ph.D. in Molecular Biology from Purdue University, West Lafayette, IN and a B.S. in Chemistry with honors from the University of Georgia. He was a postdoctoral fellow at SUNY, Stony Brook and a Research Assistant Professor at the University of Medicine and Dentistry of NJ in Piscataway.
Individual/Angel
Past Investments
NextForce Technology, PowWow Energy, 3TEN8, NeoReach, Focal Systems, RageOn, Datawallet, Rigetti Quantum Computing, Naked Labs, Rupertbot, Wyre, Axiom Exergy, Paysa, Cypherpath, Gravity Group previously Dil Mil, Polychain Capital, Voke VR, Labdoor, Ampool, Kemvi, Artinem
021 Capital
Bangalore, Karnataka, India
021 Capital is a venture capital investment firm that invests biotechnology, agrotechnology, and the internet.
Venture Capital
Private Equity Firm
Venture Capital
10X Fund LP
Niceville, Florida, United States
10X Fund LP invests principally in the biotechnology sector and is a technology-focused hedge fund based in Florida.
Biotechnology
Finance
Venture Capital
Hedge Fund
Showing 1 to
20 of
471 results